Funding for this research was provided by:
The Swedish Breast Cancer Association
The Swedish Breast Cancer Group
The Swedish Cancer Society
The Mrs. Berta Kamprad Foundation
The Anna and Edwin Berger´s Foundation
The Gustav V Jubilee Fund
Governmental Funding of Clinical Research within the Swedish National Health Service
Futurum – the Academy for Health and Care, Region Jönköping County
Received: 11 September 2020
Accepted: 30 October 2020
First Online: 23 December 2020
Ethics approval and consent to participate
: The SBII:2pre study was previously approved by both the ethical committees in Lund and Linköping, Sweden, and informed consent was obtained from all participants included in this study. The follow-up study has an ethical approval by the ethical committee of Lund (Dnr LU 2015/350). For the purpose of this study, there is an additional complementary approved application (Dnr LU 2017/97). Approval from the Biobank Sweden was achieved. This article does not contain any studies with animal data.
: Not applicable.
: Author Maria Ekholm has had a consultant/advisory role in Pfizer and Novartis. Ute Krüger has ownership in proHISTO. None of the authors has any competing interests, financial and non-financial, in relation to the work described.